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Introduction
Inflammation of the bladder is a common disease mainly
affecting women. Patients may complain of suprapubic
pain, urinary frequency and urgency with or without
haematuria on repeated occasions. In many cases, urine
analysis reveals white and red blood cells, while a positive
bacteriological culture will confirm an infectious cause of
the cystitis. However, if the culture is negative, with or
without cells, interstitial cystitis (IC) should be suspected.
IC is a poorly understood syndrome that, like bacterial
cystitis, occurs primarily in women. Lack of awareness of
IC by the physician or the use of an inappropriate
diagnostic approach may result in a lengthy period for
many patients between the onset of symptoms and
diagnosis of IC.
IC is a chronic inflammatory bladder disorder of
unknown aetiology. Bladder histology, showing infil-
trates of mast cells, eosinophilic leukocytes and T
lymphocytes, suggests that the disease is mediated by
the immune system. The clinical association of IC with
thyroid disorders and systemic autoimmune diseases
such as systemic lupus erythematosus [1] and Sjo¨gren’s
syndrome [2], has led to the hypothesis that IC may be an
autoimmune disease of the bladder. However, the
triggering factor that leads to disease is still unknown,
as is the case with the associated autoimmune diseases.
The most prevalent aetiological theories of IC are:
’ Increased permeability of the bladder epithelium,
caused by deficient glycoproteins and glycosamino-
glycans (GAGs) of the glycocalyx, allowing urine
components to damage the bladder wall.
’ Mast cell activation and degranulation by specific (IgE
binding) or nonspecific (e.g. drugs, hormones, acet-
ylcholine) stimuli, leading to the release of pre-stored
(e.g. histamine, heparin, tryptase) or de novo produced
(e.g. leukotrienes, PGs, thromboxanes) mediators of
inflammation.
’ Infiltration of the bladder wall, induced by unknown
stimuli, with lymphocytes, plasma cells, neutrophilic
and eosinophilic granulocytes, and mast cells (=
inflammation).
’ Toxic urine components
’ Occult infection
’ Increased nerve fibre density
However, none of these factors is sufficiently sub-
stantiated by experimental or clinical evidence.
In this review we present published immunological
data on the aetiology and pathogenesis, and a novel
hypothesis of how IC may be caused, based on our recent
finding of an association between IC and Sjo¨gren’s
syndrome.
Definition
There is no clear definition of IC as the clinical
symptoms and histology are not specific. The diagnosis
is essentially a syndrome diagnosis that can only be
based on the combination of chronic irritative voiding
symptoms, sterile and cytologically negative urine,
characteristic cystoscopic findings and the exclusion of
other diseases [3]. The diagnosis of IC requires a
thorough patient history, cystoscopy carried out under
anaesthesia with hydrodistension of the bladder and
deep bladder biopsies.
IC primarily occurs in women (80–85%) and typical
symptoms consist of urinary frequency, urgency, noc-
turia and pain in the lower abdominal region. The pain is
often associated with bladder filling and relieved by
urination. Many patients have periods of remission and
exacerbation, and the condition is chronic. Symptoms
may worsen perimenstrually in about half of the affected
women. Cystoscopically, IC is characterized by petechial
bladder mucosal haemorrhages (‘glomerulations’).
Severe IC is associated with reduced bladder capacity
and in rare cases with the classic Hunner’s ulcer.
There is no consensus about the need for a bladder
biopsy for the diagnosis of IC. However, in recent years
deep bladder biopsies have been considered essential for
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the diagnosis as they exclude other bladder diseases, e.g.
carcinoma and tuberculosis, while confirming the
histological abnormalities of IC.
Epidemiology
It is not surprising that it is difficult to reliably assess the
prevalence and incidence of a disease for which the
diagnosis is not firmly defined. There are consequently
few published epidemiological studies and the results are
variable. In a Finnish study the prevalence was 18.1 per
100 000 in women and 10.6 per 100 000 in the whole
population, with an annual incidence of 1.2 cases per
100 000 [4]. In the Netherlands, Bade et al. [5] calculated
a prevalence of 8–16 cases in 100 000 women. A recent
study in the USA showed a much higher prevalence of
52–67 cases per 100 000 women [6].
Pathology
On the basis of cystoscopic appearance, two types of IC
are generally recognized: the classic ulcerated type and
the early un-ulcerated type. Johansson and Fall analysed
210 patients, 146 with an ulcer type and 64 with no
ulcers; the mean age of the ulcer group was 57 years and
of the second group 38 years, suggesting that the latter
type may be an early manifestation of IC [7].
The pathology of the second type showed suburothelial
haemorrhages corresponding to glomerulations in 90%
of the patients, while mucosal ruptures were seen in 83%.
Overall, most showed only mild inflammatory changes,
but oedema and dilated vessels were frequently seen.
In the ulcer type, inflammatory changes were limited
to the lamina propria in < 90% of the patients.
Significant detrusor muscle fibrosis was seen in only
10% of the patients. Ulcerations were usually wedge-
shaped, extended down to the lamina propria and were
generally not deeper than the level of the muscularis
mucosae. The urothelium was either absent or floating
above the surface.
The inflammatory infiltrate seen in IC is predominantly
composed of T lymphocytes, with more plasma cells as the
degree of inflammation increases [8–10]. Submucosal
inflammation is associated with denuded epithelium,
ulceration and pyuria. Epithelial and basement membrane
thickness, submucosal oedema, vascular ectasia, fibrosis,
and detrusor muscle inflammation and fibrosis may also
occur but are not specific for IC [11]. An increase has been
found in the numbers of macrophages, activated lympho-
cytes and vascular endothelial cells expressing HLA class II
molecules within the submucosa [12].
The diagnostic value of mast cell counts is a subject of
controversy. Larsen et al. [13] found a highly significant
increase in the number of mast cells within the detrusor
muscle bundles in patients with IC. Lynes et al. [14] found
a strong relationship between detrusor mast cell density,
especially degranulated, and the degree of epithelial loss,
submucosal inflammation, epithelial ulceration, urinary
pyuria and response to treatment. However, recent
studies indicated that mast cell counts are not useful in
the evaluation of IC and do not allow inclusion or
exclusion of a diagnosis of IC. Furthermore, an
ultrastructural analysis of all tissue components did not
support a primary pathogenetic role of mast cells or a
selectively deficient GAG layer [15,16]
Epithelial cells of lesional and uninvolved bladder tissue
usually stain positively for IgA, which may be focal or may
diffusely involve all layers of the epithelium. Staining for
IgE correlates with the presence of mast cells and is seen in
<2% of cases, also suggesting that mast cells have no
prominent role in the pathogenesis of the disease.
Eosinophil density in bladder biopsies was uniformly low
and similar in IC and control patients. Lynes et al. [14]
found no evidence of a relationship between the eosinophil
and the inflammatory process of IC.
Electron microscopy shows a widening of the inter-
stitium between urothelial cells [17]. Elbadawi and Light
[16] found a distinctive combination of peculiar muscle cell
profiles, injury of intrinsic vessels and nerves in the
muscularis and suburothelium. A dis-cohesive urothelium
was observed in lesional and less markedly in non-lesional
bladder samples. Marked oedema of various tissue
elements and cells appeared to be common. Urothelial
changes disrupted the permeability barrier. Vascular
lesions included endothelial cell injury and suggested a
slow microcirculation. Neural changes included a combi-
nation of degenerative and regenerative features.
It can be concluded from these data that the
pathological findings in IC indicate no specific causal
mechanism, but mainly reflect the chronic inflammatory
nature of the disease.
Aetiology and pathogenesis
Aetiology
The aetiology of IC is unknown and, as in other diseases
with no known cause, many theories have been
published. IC has been suggested to be of an auto-
immune, allergic, infectious, neurological, vascular or
mechanical nature, or caused by infiltration and damage
of the bladder wall by activated mast cells, and/or an
altered bladder lining permitting entry of allergenic or
toxic substances into the underlying tissues [18,19].
Using an rDNA bacterial PCR to study bladder biopsies
and sterile urine samples from patients with IC, Haarala
et al. [20] excluded an ongoing bacterial infection as the
cause of IC.
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The role of mast cells in the bladder wall of IC is highly
controversial. The increase in the number of mast cells is
not specific for IC as it occurs in many other (chronic)
bladder diseases. Ultrastructural studies also failed to
support a primary pathogenetic role of mast cells, but a
leaky urothelium and mast cell activation may be a result
of a self-perpetuating process of neurogenic inflammation
[16].
IC is not an organ-specific disease as many patients
have systemic symptoms and blood abnormalities (see
below), suggesting that IC may be a local expression of a
generalized disease. The association of IC with systemic
lupus erythematosus has been known for a long time,
with a 30-fold increased risk, and this magnitude of
increased risk was also found with Sjo¨gren’s syndrome
[2]. Furthermore, a recent study revealed a 100-fold
increase of inflammatory bowel disease (Crohn’s disease
and ulcerative colitis) in patients with IC [21]. The
arguments in favour of an autoimmune nature of IC
are:
’ IC occurs more frequently in women than in men
’ no microorganism or other cause has been found in IC
’ IC is frequently associated with arthritis, systemic
lupus erythematosus, thyroid disorders and Sjo¨gren’s
syndrome
’ IC is often accompanied by joint pain, muscle pain,
fatigue, intestinal disorders and medicine intolerance
’ blood tests often show abnormalities such as increased
IgG, decreased C4, antinuclear antibodies (ANA) and
antibodies to mitochondria and parietal cells
’ mainly CD4+T lymphocytes are found in the inflamed
bladder wall of patients with IC.
Pathogenesis
Several studies have shown abnormalities in IC that may
play a role in the pathogenesis of the disease. A small
peptide that inhibits the proliferation of normal bladder
epithelial cells in vitro has been detected in the urine of
86% of patients with IC, in 12% of women with bacterial
cystitis and in 8% of normal control subjects [22]. This
antiproliferative factor was subsequently found to
originate from the distal ureter or urinary bladder [23].
The factor needs to be identified to fully understand its
relevance and origin in IC.
Diffusion of urinary potassium into the bladder
interstitium induces sensory symptoms and damages
tissue in IC [24]. This may be important in patients with
coexisting Sjo¨gren’s syndrome, as distal renal tubular
acidosis with increased urinary potassium excretion is
common in the latter disease.
Bade et al. [25] showed the presence of IgG auto-
antibodies against bladder epithelium and muscle fibres
in all of three patients with IC who were tested.
The chronic lymphocytic infiltrate probably causes
bladder fibrosis as this relationship is also seen in other
diseases, e.g. Crohn’s disease and sarcoidosis.
Immunology
Blood abnormalities
Sera from patients with IC showed significant depletion of
complement C4 and markedly elevated IgG levels [26],
suggesting activation of the classic complement pathway
by (auto)antibodies. Studies on peripheral blood lympho-
cyte subsets showed increased numbers of B lymphocytes
and activated lymphocytes [2,27], or were found to be
entirely normal [8]. Antinuclear antibodies (ANA) at
titres of o1 : 40 have been found in 36–60% of patients
with IC [2,28]. However, these abnormalities are not
specific and are seen in other chronic inflammatory
diseases with immunologically mediated tissue damage.
Urine abnormalities
Thirty-three urine specimens from 14 patients with IC
showed acute inflammation, predominantly polymorpho-
nuclear cells; 14 (42%) specimens contained eosinophils
and 10 (30%) contained cells resembling mast cells.
Other findings included numerous degenerated cells,
reactive transitional cells and haematuria [29]. Levels of
tryptase, a mast cell-derived enzyme in 24 h urine
samples, but not in ‘spot’ urine samples, are much
higher in patients with IC [19].
Systemic clinical features
Van de Merwe et al. [2] investigated 10 patients with IC
for the presence of systemic autoimmune diseases, in
particular for Sjo¨gren’s syndrome, which is diagnosed on
the basis of coexisting involvement of lachrymal and
salivary glands, leading to keratoconjunctivitis sicca
(KCS) and focal lymphocytic sialadenitis (FLS), respec-
tively. Other features consist of arthralgia and disabling
fatigue in 80% of the patients. Serological abnormalities
include antinuclear antibodies, rheumatoid factors and
antibodies to SS-A/Ro and SS-B/La. In two patients both
KCS and FLS were present, thus diagnosing Sjo¨gren’s
syndrome. Additionally, in six patients one of these two
features was present; KCS in three and FLS in three.
Unpublished data (van de Merwe, Arendsen and
Hooijkaas) of a preliminary analysis of 80 patients with
IC showed that 14% also had Sjo¨gren’s syndrome, 26%
KCS and 5% FLS.
Alagiri et al. [21] conducted a questionnaire-based
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study evaluating 12 disease processes and surveying the
characteristics of IC in a population of 2405 individuals
with IC who responded to the initial survey; an additional
277 individuals were randomly selected and individually
contacted. Compared with the general population,
individuals with IC were 100 times more likely to have
inflammatory bowel disease (7.3%, population 0.07%)
and 30–50 times more likely to have systemic lupus
erythematosus (1.7%, population 0.05%). In addition,
there were increased frequencies of allergies (40.6%;
population 22.5%), irritable bowel syndrome (25.4%,
population 2.9%), sensitive skin (22.6%, population
10.6%), and fibromyalgia (12.8%, population 3.2%)
[21,30] in patients with IC.
Hypothesis
If it is true that IC, systemic lupus erythematosus and
Sjo¨gren’s syndrome are all expressions of a comparable
disturbed immunological mechanism, recent and intri-
guing findings in Sjo¨gren’s syndrome may be relevant for
IC. Sjo¨gren’s syndrome is an autoimmune exocrinopathy
with general mucosal dryness and systemic symptoms.
Histologically it is characterized by periductal focal
infiltration of exocrine glands with mainly T lympho-
cytes. In patients and animal models the infiltration of
exocrine glands does not fully explain the lack of
secretory function of the glands. Additionally, auto-
antibodies to the acetylcholine receptors, e.g. the
muscarinic M3-receptors, in salivary and lachrymal
glands can functionally block these receptors [31,32].
This can partly be overcome by muscarinic agonists such
as pilocarpine hydrochloride [33,34]. Autoantibodies to
the muscarinic M1-receptor have also been detected in
patients with Sjo¨gren’s syndrome [35]. Myasthenia
gravis, an autoimmune disease also associated with
Sjo¨gren’s syndrome and systemic lupus erythematosus, is
mediated by autoantibodies to the nicotinic acetylcholine
receptor at the surface of striated muscles [36].
Studies on Graves’ disease have clearly shown that
antibodies to the thyroid-stimulating hormone receptor
may stimulate or block receptor functions, or even show
alternating stimulation and blocking in time within the
same patients [37].
The human detrusor smooth muscle is endowed with
muscarinic M1-, M2-, and M3-receptors, with direct and
indirect effects on smooth muscle contraction [38,39].
Furthermore, carbachol, a muscarinic receptor agonist,
has been found to trigger serotonin release from rat
bladder mast cells in a dose-dependent manner, an effect
increased by pre-treating tissue with oestradiol, and that
is blocked by atropine [40]. Recently, IgG autoantibodies
against epithelium and muscle fibres were found in
patients with IC [25].
Stimulating and/or blocking autoantibodies to various
subtypes of muscarinic receptors could theoretically be
responsible for both exocrine dysfunction and detrusor
smooth muscle contractions. It is well known that
antibodies can attract inflammatory cells to the sites of
their antigen binding as a consequence of the activation
of complement proteins, with the release of chemotactic
fragments. The observation that inflammatory infiltrates
are mainly seen in late stages of the disease [7] is in line
with this hypothesis.
Summary
IC is a complex syndrome consisting of urinary voiding
symptoms, lower abdominal pain and signs of chronic
inflammation at cystoscopy and pathology. The cause of
the disease is unknown but the infiltration of the bladder
wall by mainly T lymphocytes in addition to mast cells,
the occurrence of autoantibodies in many patients and
the association with systemic autoimmune diseases
suggest an autoimmune nature of the disease.
The strong association of IC with Sjo¨gren’s syndrome
warrants the exploration of comparable mechanisms in
both diseases. Recent data on Sjo¨gren’s syndrome suggest
that initial abnormalities may consist of autoantibodies
to the muscarinic M3- receptors, causing impaired
nervous stimulation of the exocrine glands.
Inflammatory changes may be a late consequence of
the binding of these autoantibodies to the receptors. It is
postulated that autoantibodies to various subtypes of
muscarinic receptors on detrusor smooth muscle could
theoretically explain initial voiding symptoms and late
inflammatory changes in the bladder in IC and the
association of IC with Sjo¨gren’s syndrome.
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